June 2026
1. LIEBE R, Lammert F, Schmidt HH, Krawczyk M, et al
   Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies.
   Gut. 2026 Jun 17:gutjnl-2025-337027. doi: 10.1136/gutjnl-2025-337027.
   

   >> Share

   
   
2. BACKHAUS M, Mainardi L, Raggi C, Schneider KM, et al
   Cancer neuroscience in cholangiocarcinoma: from perineural invasion to neuroimmune control.
   Gut. 2026 Jun 17:gutjnl-2026-338969. doi: 10.1136/gutjnl-2026-338969.
   

   >> Share

   
   
3. WELSCH L, Eickhoff A
   Environmental impacts of single-use versus reusable duodenoscopes for endoscopic retrograde cholangiopancreatography in Germany: an ISO-compliant cradle-to-grave life cycle assessment.
   Gut. 2026 Jun 3:gutjnl-2026-338166. doi: 10.1136/gutjnl-2026-338166.
   

   >> Share

   
   May 2026
4. JAGTAP N, Rughwani H, Talukdar R, Chavan D, et al
   Urgent versus early ERCP in mild-to-moderate acute cholangitis: a randomised controlled trial.
   Gut. 2026 May 20:gutjnl-2025-337279. doi: 10.1136/gutjnl-2025-337279.
   

   >> Share

   
   
5. JIRAPINYO P, Schlottmann F, Buxhoeveden R, Lautz D, et al
   Metabolic mechanisms of duodeno-ileal diversion: early bile acid and incretin signalling predict glycaemic outcomes.
   Gut. 2026 May 6:gutjnl-2026-338307. doi: 10.1136/gutjnl-2026-338307.
   

   >> Share

   
   
6. CUBERO FJ, Macias RIR
   Tumour-autonomous IL-6 signalling creates a metabolic vulnerability in intrahepatic cholangiocarcinoma.
   Gut. 2026 May 4:gutjnl-2026-338744. doi: 10.1136/gutjnl-2026-338744.
   

   >> Share

   
   April 2026
7. MENG XL, Lu JC, Zhang YX, Pu P, et al
   Norepinephrine promotes tumour cell aggressiveness and NK cell ferroptosis via ADRB2 in intrahepatic cholangiocarcinoma with perineural invasion.
   Gut. 2026 Apr 20:gutjnl-2025-337595. doi: 10.1136/gutjnl-2025-337595.
   

   >> Share

   
   March 2026
8. AWONIYI M, El Hag M, Hernandez J, Yang Q, et al
   Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model.
   Gut. 2026 Mar 23:gutjnl-2025-336675. doi: 10.1136/gutjnl-2025-336675.
   

   >> Share

   
   
9. GEHL V, O'Rourke CJ, Cornillet M, Nousias O, et al
   Molecular and cellular consequences of tumour-autonomous IL-6 signalling in intrahepatic cholangiocarcinoma.
   Gut. 2026 Mar 19:gutjnl-2025-337579. doi: 10.1136/gutjnl-2025-337579.
   

   >> Share

   
   February 2026
10. ROMEO M, Dallio M, Di Nardo F, Napolitano C, et al
    Beyond gastrointestinal symptom burden: exploring the impact of previous cholecystectomy on ultrasound-based hepatocellular carcinoma surveillance in patients with liver cirrhosis.
    Gut. 2026 Feb 3:gutjnl-2026-338023. doi: 10.1136/gutjnl-2026-338023.
    

    >> Share

    
    
11. CHEN L, Li P, Park MJ, Chen Z, et al
    CPS1: a multipurpose mitochondrial enzyme, bile protein, acute liver injury biomarker, and cytokine.
    Gut. 2026 Feb 2:gutjnl-2024-333082. doi: 10.1136/gutjnl-2024-333082.
    

    >> Share

    
    January 2026
12. VIJAY-KUMAR M, Yeoh BS, Gewirtz AT
    Hydroxylation matters! Microbial bile acid metabolism and colorectal cancer.
    Gut. 2026 Jan 28:gutjnl-2025-337583. doi: 10.1136/gutjnl-2025-337583.
    

    >> Share

    
    
13. SUKUBO NG, Caime C, Gerussi A, Invernizzi P, et al
    Kupffer cell autophagy emerges as a central regulator of immune dysregulation in primary biliary cholangitis.
    Gut. 2026 Jan 27:gutjnl-2025-337652. doi: 10.1136/gutjnl-2025-337652.
    

    >> Share

    
    
14. WEBSTER GJ BSC MD FRCP
    Commentary on: gutjnl-2025-335548.R2-endoscopic retrograde cholangiopancreatography (ERCP) services across the UK.
    Gut. 2026 Jan 6:gutjnl-2025-337099. doi: 10.1136/gutjnl-2025-337099.
    

    >> Share

    
    December 2025
15. OSSWALD A, Wortmann E, Wylensek D, Kuhls S, et al
    Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer.
    Gut. 2025 Dec 18:gutjnl-2024-332243. doi: 10.1136/gutjnl-2024-332243.
    

    >> Share

    
    
16. LUO PY, Ma M, Liu MC, Wu YH, et al
    Autophagy of Kupffer cells modulates CD8(+) T cell activation in primary biliary cholangitis.
    Gut. 2025 Dec 10:gutjnl-2025-335611. doi: 10.1136/gutjnl-2025-335611.
    

    >> Share

    
    
17. CORRALES F, Cardinale V
    Multiomics- and artificial intelligence-powered research platforms for enhancing understanding and prediction of the cholangiocarcinoma patient journey.
    Gut. 2025 Dec 4:gutjnl-2025-337219. doi: 10.1136/gutjnl-2025-337219.
    

    >> Share

    
    
18. ZHOU H, Li H, Wu N, Calvisi DF, et al
    SIRT6-GLUL axis: rewiring nitrogen metabolism in intrahepatic cholangiocarcinoma.
    Gut. 2025 Dec 3:gutjnl-2025-337554. doi: 10.1136/gutjnl-2025-337554.
    

    >> Share

    
    October 2025
19. WANG S, Guo Z, Sun B, Liu K, et al
    Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer.
    Gut. 2025 Oct 28:gutjnl-2025-335513. doi: 10.1136/gutjnl-2025-335513.
    

    >> Share

    
    
20. ZHANG M, Chen C, Zhang H, Long T, et al
    SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL.
    Gut. 2025 Oct 23:gutjnl-2025-335729. doi: 10.1136/gutjnl-2025-335729.
    

    >> Share

    
    
21. RUILOVA SOSORANGA E, Tack J
    Insulin-like peptide 5: a new key player in IBS with diarrhoea and bile acid malabsorption?
    Gut. 2025 Oct 17:gutjnl-2025-336390. doi: 10.1136/gutjnl-2025-336390.
    

    >> Share

    
    
22. 
    Correction: Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer.
    Gut. 2025;74:e21.
    

    >> Share

    
    
23. SIRTL S, Zorniak M, Mayerle J
    Response to 'Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?'.
    Gut. 2025 Oct 5:gutjnl-2025-337089. doi: 10.1136/gutjnl-2025-337089.
    

    >> Share

    
    September 2025
24. SHEN Y, Jin X, Song W, Fang T, et al
    Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies.
    Gut. 2025 Sep 29:gutjnl-2025-335904. doi: 10.1136/gutjnl-2025-335904.
    

    >> Share

    
    
25. LOZANO E, Vaquero J
    Aurora kinase B at the nexus of cholesterol metabolism and therapy response in cholangiocarcinoma.
    Gut. 2025 Sep 27:gutjnl-2025-336445. doi: 10.1136/gutjnl-2025-336445.
    

    >> Share

    
    
26. MENDONCA PROENCA I, Lera Dos Santos ME, Maluf-Filho F
    Biliary sludge and microlithiasis: are we covering the full spectrum of lithogenic biliary disorders?
    Gut. 2025 Sep 19:gutjnl-2025-336609. doi: 10.1136/gutjnl-2025-336609.
    

    >> Share

    
    
27. AHMED W, Haworth E, Sharp L, Dobson C, et al
    Endoscopic Retrograde Cholangiopancreatography (ERCP) services across the UK.
    Gut. 2025 Sep 10:gutjnl-2025-335548. doi: 10.1136/gutjnl-2025-335548.
    

    >> Share

    
    August 2025
28. MILARDI G, Franceschini B, Camisaschi C, Puccio S, et al
    Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome.
    Gut. 2025 Aug 31:gutjnl-2025-334861. doi: 10.1136/gutjnl-2025-334861.
    

    >> Share

    
    
29. KONINGS B, Balsiger LM, Hreinsson JP, Simren M, et al
    Global prevalence and gastrointestinal symptom burden of individuals with a history of cholecystectomy.
    Gut. 2025 Aug 12:gutjnl-2024-334531. doi: 10.1136/gutjnl-2024-334531.
    

    >> Share

    
    
30. MERCADO-GOMEZ M, Goikoetxea-Usandizaga N, Gine AE, Merlos Rodrigo MA, et al
    Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential.
    Gut. 2025 Aug 5:gutjnl-2024-333255. doi: 10.1136/gutjnl-2024-333255.
    

    >> Share

    
    
31. VILLA E
    CNNM4: a ferroptotic vulnerability in cholangiocarcinoma.
    Gut. 2025 Aug 5:gutjnl-2025-335061. doi: 10.1136/gutjnl-2025-335061.
    

    >> Share

    
    July 2025
32. LIU F, Chen W, Zhang Z, Zeng W, et al
    Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma.
    Gut. 2025 Jul 31:gutjnl-2025-335291. doi: 10.1136/gutjnl-2025-335291.
    

    >> Share

    
    
33. BANNON CA, Walters JRF, Wu T, Kay RG, et al
    Insulin-like peptide 5 is released in response to bile acid in the rectum and is associated with diarrhoea severity in patients with bile acid diarrhoea.
    Gut. 2025 Jul 23:gutjnl-2025-335393. doi: 10.1136/gutjnl-2025-335393.
    

    >> Share

    
    
34. MORALI K, Vicent S
    To be or not to be (a biliary cancer): RAS (signalling) is the question.
    Gut. 2025 Jul 15:gutjnl-2025-335690. doi: 10.1136/gutjnl-2025-335690.
    

    >> Share

    
    June 2025
35. LOU C, Lan T, Xu S, Hu X, et al
    Heterogeneity and plasticity of cholangiocytes in liver injury: a journey from pathophysiology to therapeutic utility.
    Gut. 2025 Jun 9:gutjnl-2025-334763. doi: 10.1136/gutjnl-2025-334763.
    

    >> Share

    
    
36. ZHU C, Boucheron N, Al-Rubaye O, Chung BK, et al
    24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting T(H)17 pathogenicity and transdifferentiation.
    Gut. 2025;74:1079-1093.
    

    >> Share

    
    
37. ZHANG W, Tao L, Wang F, Shao B, et al
    Endoscopic mucosal resection in the pancreatobiliary system under direct cholangiopancreatoscopic guidance.
    Gut. 2025 Jun 6:gutjnl-2025-335707. doi: 10.1136/gutjnl-2025-335707.
    

    >> Share

    
    May 2025
38. LI P, Lei Q, Yu X, Shen Y, et al
    Commensal Bacteroides T6SS alleviate GI-aGVHD via mediating gut microbiota composition and bile acids metabolism.
    Gut. 2025 May 28:gutjnl-2024-334565. doi: 10.1136/gutjnl-2024-334565.
    

    >> Share

    
    
39. ROSNER T, Rupp C, Lechler C, Bauer U, et al
    Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer.
    Gut. 2025 May 12:gutjnl-2024-333238. doi: 10.1136/gutjnl-2024-333238.
    

    >> Share

    
    
40. HE Y, Kostallari E
    When getting reactive becomes the nORM: the emerging roles of proinflammatory cholangiokines.
    Gut. 2025 May 7:gutjnl-2025-335426. doi: 10.1136/gutjnl-2025-335426.
    

    >> Share

    
    April 2025
41. LIU H, Yin G, Franco Leonardi B, Lan T, et al
    Reactive cholangiocyte-derived ORM2 drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming.
    Gut. 2025 Apr 8:gutjnl-2024-334425. doi: 10.1136/gutjnl-2024-334425.
    

    >> Share

    
    
42. ZHURAVLEVA E, Lewinska M, O'Rourke CJ, Pea A, et al
    Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma.
    Gut. 2025;74:804-814.
    

    >> Share

    
    March 2025
43. TAN L, Wu WKK
    24-Nor-ursodeoxycholic acid: a novel treatment targeting T-cell-mediated immune dysregulation in primary sclerosing cholangitis and beyond.
    Gut. 2025 Mar 26:gutjnl-2025-334966. doi: 10.1136/gutjnl-2025-334966.
    

    >> Share

    
    February 2025
44. BANG JY, Faraj Agha M, Hawes R, Varadarajulu S, et al
    Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction.
    Gut. 2025 Feb 26:gutjnl-2025-334979. doi: 10.1136/gutjnl-2025-334979.
    

    >> Share

    
    December 2024
45. LIM Y, Kang S, Shah A, Holtmann G, et al
    Is the biogeography of the mucosa-associated microbiota a key factor affecting primary sclerosing cholangitis disease course and treatment?
    Gut. 2024 Dec 20:gutjnl-2024-334069. doi: 10.1136/gutjnl-2024-334069.
    

    >> Share

    
    
46. HOLLENBACH M, Heise C, Abou-Ali E, Gulla A, et al
    Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis.
    Gut. 2024 Dec 12:gutjnl-2022-327996. doi: 10.1136/gutjnl-2022-327996.
    

    >> Share

    
    
47. DESERT R, Goyal L, Baumert TF
    Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment.
    Gut. 2024 Dec 6:gutjnl-2024-333632. doi: 10.1136/gutjnl-2024-333632.
    

    >> Share

    
    October 2024
48. ONNEKINK AM, Gorris M, Bekkali NL, Bos P, et al
    Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial.
    Gut. 2024 Oct 10:gutjnl-2024-332695. doi: 10.1136/gutjnl-2024-332695.
    

    >> Share

    
    September 2024
49. ELURBIDE J, Colyn L, Latasa MU, Uriarte I, et al
    Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.
    Gut. 2024 Sep 11:gutjnl-2024-332998. doi: 10.1136/gutjnl-2024-332998.
    

    >> Share

    
    
50. COTE GA, Elmunzer BJ, Nitchie H, Kwon RS, et al
    Sphincterotomy for biliary sphincter of Oddi disorder and idiopathic acute recurrent pancreatitis: the RESPOnD longitudinal cohort.
    Gut. 2024 Sep 7:gutjnl-2024-332686. doi: 10.1136/gutjnl-2024-332686.
    

    >> Share

    
    August 2024
51. SHI C, Hong J, Bai B, Li S, et al
    Morphological consistency between EUS and ERCP in diagnosing biliary sludge and microlithiasis.
    Gut. 2024 Aug 22:gutjnl-2024-332971. doi: 10.1136/gutjnl-2024-332971.
    

    >> Share

    
    
52. KHAN SA, Rushbrook SM, Kendall TJ, Zen Y, et al
    Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
    Gut. 2024 Aug 19:gutjnl-2024-333359. doi: 10.1136/gutjnl-2024-333359.
    

    >> Share

    
    July 2024
53. HOV JR
    Sclerosing cholangitis and inflammatory bowel disease: a paradoxical relationship?
    Gut. 2024 Jul 17:gutjnl-2024-332835. doi: 10.1136/gutjnl-2024-332835.
    

    >> Share

    
    June 2024
54. KEGGENHOFF FL, Castven D, Becker D, Stojkovic S, et al
    PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.
    Gut. 2024 Jun 10:gutjnl-2023-331237. doi: 10.1136/gutjnl-2023-331237.
    

    >> Share

    
    
55. BEDKE T, Stumme F, Tomczak M, Steglich B, et al
    Protective function of sclerosing cholangitis on IBD.
    Gut. 2024 Jun 5:gutjnl-2023-330856. doi: 10.1136/gutjnl-2023-330856.
    

    >> Share

    
    May 2024
56. HE H, Chen S, Yu Y, Fan Z, et al
    Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer.
    Gut. 2024 May 6:gutjnl-2023-331773. doi: 10.1136/gutjnl-2023-331773.
    

    >> Share

    
    April 2024
57. 
    Correction: Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Gut. 2024 Apr 23:gutjnl-2016-312278corr1. doi: 10.1136/gutjnl-2016-312278.
    

    >> Share

    
    
58. FABRIS L, Pol J
    Mast cells and histamine in cholangiocarcinoma: exploring overlooked avenues for enhanced patient management.
    Gut. 2024 Apr 18:gutjnl-2024-332288. doi: 10.1136/gutjnl-2024-332288.
    

    >> Share

    
    
59. BANG JY, Arnoletti JP, Wagner A, Varadarajulu S, et al
    EUS-guided gallbladder drainage in acute cholecystitis: response to letter to the editor.
    Gut. 2024 Apr 12:gutjnl-2024-332342. doi: 10.1136/gutjnl-2024-332342.
    

    >> Share

    
    March 2024
60. HAYLER R, Tuft C, Fisher O
    Head of pancreas mass with biliary obstruction: an unusual cause.
    Gut. 2024 Mar 22:gutjnl-2024-332268. doi: 10.1136/gutjnl-2024-332268.
    

    >> Share

    
    
61. LARGHI A, van Wanrooij RLJ, Bronswijk M, Vanella G, et al
    Cholecystectomy following EUS-guided gallbladder drainage in patients with acute cholecystitis at high surgical risk: friend or foe?
    Gut. 2024 Mar 22:gutjnl-2024-332273. doi: 10.1136/gutjnl-2024-332273.
    

    >> Share

    
    
62. SHI A, Liu Z, Fan Z, Li K, et al
    Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment.
    Gut. 2024 Mar 8:gutjnl-2023-331715. doi: 10.1136/gutjnl-2023-331715.
    

    >> Share

    
    January 2024
63. TOTH R, Brindley PJ, Vaquero J
    Enhancing the opportunities for cholangiocarcinoma precision therapy.
    Gut. 2024 Jan 16:gutjnl-2023-331480. doi: 10.1136/gutjnl-2023-331480.
    

    >> Share

    
    December 2023
64. HANNEMANN A, Mayerle J, Beyer G
    Response to: Correspondence on 'Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion' by Wang et al.
    Gut. 2023 Dec 2:gutjnl-2023-331525. doi: 10.1136/gutjnl-2023-331525.
    

    >> Share

    
    November 2023
65. BANG JY, Arnoletti JP, Wagner A, Varadarajulu S, et al
    EUS-guided gallbladder drainage in acute cholecystitis: long-term problems with surgical approach.
    Gut. 2023 Nov 24:gutjnl-2023-331245. doi: 10.1136/gutjnl-2023-331245.
    

    >> Share

    
    
66. HONG JH, Yong CH, Heng HL, Chan JY, et al
    Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.
    Gut. 2023 Nov 24:gutjnl-2023-330483. doi: 10.1136/gutjnl-2023-330483.
    

    >> Share

    
    
67. FRITZSCHE JA, Smit E, Ponsioen CY, Voermans RP, et al
    Time to focus on the real potential benefit of endobiliary radiofrequency ablation: stent patency in patients with cholangiocarcinoma.
    Gut. 2023 Nov 21:gutjnl-2023-331359. doi: 10.1136/gutjnl-2023-331359.
    

    >> Share

    
    
68. CHEN L, Qiu W, Sun X, Gao M, et al
    Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis.
    Gut. 2023 Nov 9:gutjnl-2023-330784. doi: 10.1136/gutjnl-2023-330784.
    

    >> Share

    
    
69. NAKAGAMI S, Morita T, Yazumi S
    Rare cause of obstructive jaundice.
    Gut. 2023 Nov 6:gutjnl-2023-330496. doi: 10.1136/gutjnl-2023-330496.
    

    >> Share

    
    October 2023
70. ARECHEDERRA M, Casadei Gardini A, Raggi C
    More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma.
    Gut. 2023 Oct 27:gutjnl-2023-331119. doi: 10.1136/gutjnl-2023-331119.
    

    >> Share

    
    
71. WANG F, Peng L, Liu Y
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion.
    Gut. 2023 Oct 10:gutjnl-2023-331163. doi: 10.1136/gutjnl-2023-331163.
    

    >> Share

    
    
72. LI JS, Fang J, Li ZS
    Endoluminal radiofrequency ablation prior to stenting for malignant biliary obstruction: really time to say goodbye?
    Gut. 2023 Oct 5:gutjnl-2023-331070. doi: 10.1136/gutjnl-2023-331070.
    

    >> Share

    
    
73. ZECHER BF, Ellinghaus D, Schloer S, Niehrs A, et al
    HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells.
    Gut. 2023 Oct 3:gutjnl-2023-329524. doi: 10.1136/gutjnl-2023-329524.
    

    >> Share

    
    September 2023
74. RUSHBROOK SM, Kendall TJ, Zen Y, Albazaz R, et al
    British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
    Gut. 2023 Sep 28:gutjnl-2023-330029. doi: 10.1136/gutjnl-2023-330029.
    

    >> Share

    
    
75. O'ROURKE CJ, Salati M, Rae C, Carpino G, et al
    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
    Gut. 2023 Sep 27:gutjnl-2023-330748. doi: 10.1136/gutjnl-2023-330748.
    

    >> Share

    
    August 2023
76. JAROSOVA J, Zarivnijova L, Cibulkova I, Mares J, et al
    Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial.
    Gut. 2023 Aug 31:gutjnl-2023-329700. doi: 10.1136/gutjnl-2023-329700.
    

    >> Share

    
    July 2023
77. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    

    >> Share

    
    April 2023
78. LEWINSKA M, Karhus ML, Ellegaard AG, Romero-Gomez M, et al
    Serum lipidome unravels a diagnostic potential in bile acid diarrhoea.
    Gut. 2023 Apr 18:gutjnl-2022-329213. doi: 10.1136/gutjnl-2022-329213.
    

    >> Share

    
    
79. ZORNIAK M, Sirtl S, Beyer G, Mahajan UM, et al
    Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis.
    Gut. 2023 Apr 18:gutjnl-2022-327955. doi: 10.1136/gutjnl-2022-327955.
    

    >> Share

    
    February 2023
80. HALLENSLEBEN ND, Stassen PMC, Schepers NJ, Besselink MG, et al
    Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study.
    Gut. 2023 Feb 27:gutjnl-2022-328258. doi: 10.1136/gutjnl-2022-328258.
    

    >> Share

    
    
81. BEYER G, Kasprowicz F, Hannemann A, Aghdassi A, et al
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: a population-based, cross-sectional cohort study.
    Gut. 2023 Feb 24:gutjnl-2021-326106. doi: 10.1136/gutjnl-2021-326106.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share